$10.66
9.90% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US6412881053
Symbol
NPCE

NeuroPace Inc Stock price

$10.66
+4.31 67.87% 1M
+3.13 41.57% 6M
+0.35 3.39% YTD
+1.80 20.32% 1Y
-1.35 11.24% 3Y
-6.34 37.29% 5Y
-6.34 37.29% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.96 9.90%
ISIN
US6412881053
Symbol
NPCE
Sector

Key metrics

Market capitalization $318.18m
Enterprise Value $334.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.38
P/S ratio (TTM) P/S ratio 4.16
P/B ratio (TTM) P/B ratio 32.32
Revenue growth (TTM) Revenue growth 27.00%
Revenue (TTM) Revenue $76.45m
EBIT (operating result TTM) EBIT $-23.07m
Free Cash Flow (TTM) Free Cash Flow $-16.79m
Cash position $56.83m
EPS (TTM) EPS $-0.99
P/E forward negative
P/S forward 4.02
EV/Sales forward 4.23
Short interest 3.13%
Show more

Is NeuroPace Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

NeuroPace Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a NeuroPace Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a NeuroPace Inc forecast:

Buy
86%
Hold
14%

Financial data from NeuroPace Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
76 76
27% 27%
100%
- Direct Costs 20 20
19% 19%
26%
56 56
30% 30%
74%
- Selling and Administrative Expenses 55 55
4% 4%
72%
- Research and Development Expense 23 23
12% 12%
30%
-21 -21
29% 29%
-28%
- Depreciation and Amortization 1.73 1.73
11% 11%
2%
EBIT (Operating Income) EBIT -23 -23
28% 28%
-30%
Net Profit -28 -28
26% 26%
-37%

In millions USD.

Don't miss a Thing! We will send you all news about NeuroPace Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroPace Inc Stock News

Neutral
Seeking Alpha
13 days ago
NeuroPace, Inc. (NASDAQ:NPCE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Jeremy Feffer – Investor Relations Joel Becker – Chief Executive Officer Rebecca Kuhn – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Mike Kratky – Leerink Partners Vik Chopra – Wells Fargo Ross Osborn – Cantor Fitzgerald Michael P...
Neutral
GlobeNewsWire
22 days ago
The RNS System Post-Approval Study (PAS) is the largest prospective post-approval study in neuromodulation for patients with drug - resistant focal epilepsy
Neutral
GlobeNewsWire
about one month ago
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 ...
More NeuroPace Inc News

Company Profile

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Head office United States
CEO Joel Becker
Employees 171
Founded 1997
Website www.neuropace.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today